HTG Molecular Diagnostics, Inc. (HTGMQ)
OTCMKTS
· Delayed Price · Currency is USD
0.0002
-0.0001 (-33.33%)
At close: Dec 26, 2024
HTG Molecular Diagnostics Revenue
HTG Molecular Diagnostics had revenue of $1.03M in the quarter ending March 31, 2023, a decrease of -12.83%. This brings the company's revenue in the last twelve months to $6.21M, down -28.21% year-over-year. In the year 2022, HTG Molecular Diagnostics had annual revenue of $6.37M, down -28.52%.
Revenue (ttm)
6.21M
Revenue Growth
-28.21%
P/S Ratio
n/a
Revenue / Employee
115.08K
Employees
54
Market Cap
2.00
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 6.37M | -2.54M | -28.52% |
Dec 31, 2021 | 8.91M | 357.96K | 4.19% |
Dec 31, 2020 | 8.55M | -10.66M | -55.48% |
Dec 31, 2019 | 19.20M | -2.30M | -10.70% |
Dec 31, 2018 | 21.50M | 6.74M | 45.69% |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Dec 31, 2013 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sandoz Group AG | 10.11B |
Telix Pharmaceuticals Limited | 430.80M |
Elekta AB (publ) | 1.66B |
Ryman Healthcare Limited | 458.44M |
Verano Holdings Corp. | 897.57M |
Vireo Growth Inc. | 98.53M |
Medexus Pharmaceuticals Inc. | 104.76M |